Tredje Ap Fonden Eli Lilly & CO Transaction History

Tredje Ap Fonden

$10.8 Billion
Q3 2024

A detailed history of Tredje Ap Fonden transactions in Eli Lilly & CO stock. As of the latest transaction made, Tredje Ap Fonden holds 207,103 shares of LLY stock, worth $155 Million. This represents 1.7% of its overall portfolio holdings.

Number of Shares

207,103

Previous 229,293 9.68%

Holding current value

$155 Million

Previous $208 Million 11.62%

% of portfolio

1.7%

Previous 2.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$772.14 - $960.02 $17.1 Million - $21.3 Million	-22,190 Reduced 9.68%	207,103 $183 Million
Q2 2024 Aug 12, 2024	BUY	$724.87 - $909.04 $7.25 Million - $9.09 Million	10,000 Added 4.56%	229,293 $208 Million
Q1 2024 May 13, 2024	BUY	$592.2 - $792.28 $11.5 Million - $15.4 Million	19,500 Added 9.76%	219,293 $171 Million
Q4 2023 Feb 12, 2024	BUY	$525.19 - $619.13 $3.77 Million - $4.44 Million	7,170 Added 3.72%	199,793 $116 Million
Q3 2023 Nov 09, 2023	BUY	$434.7 - $599.3 $721,167 - $994,238	1,659 Added 0.87%	192,623 $103 Million
Q2 2023 Aug 11, 2023	BUY	$350.74 - $468.98 $18.4 Million - $24.6 Million	52,367 Added 37.78%	190,964 $89.6 Million
Q1 2023 May 10, 2023	BUY	$310.63 - $364.82 $3.47 Million - $4.08 Million	11,170 Added 8.77%	138,597 $47.6 Million
Q4 2022 Feb 10, 2023	BUY	$321.55 - $374.67 $12.5 Million - $14.6 Million	38,996 Added 44.1%	127,427 $46.6 Million
Q3 2022 Nov 10, 2022	SELL	$296.48 - $337.87 $8.46 Million - $9.64 Million	-28,534 Reduced 24.4%	88,431 $28.6 Million
Q2 2022 Aug 10, 2022	BUY	$278.73 - $327.27 $1.11 Million - $1.31 Million	4,000 Added 3.54%	116,965 $37.9 Million
Q1 2022 May 09, 2022	BUY	$234.69 - $291.66 $3.87 Million - $4.81 Million	16,500 Added 17.1%	112,965 $32.4 Million
Q4 2021 Feb 10, 2022	SELL	$224.85 - $279.04 $1.59 Million - $1.97 Million	-7,051 Reduced 6.81%	96,465 $26.6 Million
Q3 2021 Nov 10, 2021	BUY	$221.6 - $272.71 $22.9 Million - $28.2 Million	103,516 New	103,516 $23.9 Million
Q2 2021 Aug 06, 2021	SELL	$180.55 - $233.54 $49.4 Million - $63.9 Million	-273,516 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$164.32 - $212.72 $14 Million - $18.1 Million	85,000 Added 45.09%	273,516 $51.1 Million
Q4 2020 Feb 12, 2021	SELL	$130.46 - $172.63 $7.83 Million - $10.4 Million	-60,000 Reduced 24.14%	188,516 $31.8 Million
Q3 2020 Nov 10, 2020	SELL	$146.22 - $169.13 $19 Million - $22 Million	-130,000 Reduced 34.34%	248,516 $36.8 Million
Q2 2020 Aug 11, 2020	BUY	$136.42 - $164.18 $34.4 Million - $41.4 Million	251,894 Added 198.93%	378,516 $62.1 Million
Q1 2020 May 11, 2020	BUY	$119.05 - $147.35 $2.67 Million - $3.3 Million	22,408 Added 21.5%	126,622 $18 Million
Q4 2019 Feb 10, 2020	SELL	$106.92 - $132.43 $3.64 Million - $4.5 Million	-34,000 Reduced 24.6%	104,214 $13.7 Million
Q3 2019 Nov 12, 2019	BUY	$106.79 - $116.16 $70,908 - $77,130	664 Added 0.48%	138,214 $15.5 Million
Q2 2019 Aug 09, 2019	BUY	$110.79 - $129.32 $101,483 - $118,457	916 Added 0.67%	137,550 $15.2 Million
Q1 2019 May 10, 2019	SELL	$111.31 - $131.02 $355,301 - $418,215	-3,192 Reduced 2.28%	136,634 $17.7 Million
Q4 2018 Feb 11, 2019	SELL	$105.9 - $118.64 $5.8 Million - $6.5 Million	-54,752 Reduced 28.14%	139,826 $16.2 Million
Q3 2018 Nov 13, 2018	SELL	$85.86 - $107.31 $5.72 Million - $7.15 Million	-66,658 Reduced 25.52%	194,578 $20.9 Million
Q2 2018 Aug 09, 2018	BUY	$75.7 - $86.88 $4.47 Million - $5.13 Million	59,103 Added 29.24%	261,236 $22.3 Million
Q1 2018 May 09, 2018	BUY	$74.21 - $87.6 $875,381 - $1.03 Million	11,796 Added 6.2%	202,133 $15.6 Million
Q4 2017 Feb 12, 2018	BUY	$81.94 - $87.89 $798,095 - $856,048	9,740 Added 5.39%	190,337 $16.1 Million
Q3 2017 Nov 13, 2017	BUY	$77.07 - $85.54 $13.9 Million - $15.4 Million	180,597	180,597 $15.4 Million

Others Institutions Holding LLY

# of Institutions

4,003

Shares Held

752M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $709B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tredje Ap Fonden, based on Form 13F filings with the SEC.

News

Stay updated on Tredje Ap Fonden with notifications on news.

Account